In our work, we found that NF-κB induced the expression of CXCL1, ICAM1 and TNFAIP3 after doxorubicin treatment only in a subset of tumors, suggesting that differences in responses may exist among tumor subtypes. Here, CXCL1 is linked to neoplasm.